Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: Effect of phosphate binders

Nephrology Dialysis Transplantation

Volumn 28, Issue 10, 2013, Pages 2510-2517

  De Oliveira, Rodrigo B ^a   Graciolli, Fabiana G ^a   Dos Reis, Luciene M ^a   Cancela, Ana L E ^a   Cuppari, Lilian ^b   Canziani, Maria E ^b   Carvalho, Aluizio B ^b   Jorgetti, Vanda ^a   Moysés, Rosa M A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

adipokines; chronic kidney disease; fibroblast growth factor 23; phosphate binders.; Wnt catenin signalling

Indexed keywords

25 HYDROXYVITAMIN D; ADIPONECTIN; ALKALINE PHOSPHATASE BONE ISOENZYME; BETA CATENIN; CALCIUM; CALCIUM ACETATE; CREATININE; DEOXYPYRIDINOLINE; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR 23; LEPTIN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SCLEROSTIN; SEROTONIN; SEVELAMER; WNT PROTEIN;

ADULT; ARTICLE; BONE LEVEL; BONE METABOLISM; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG EFFECT; ENERGY METABOLISM; FEMALE; HUMAN; HYPERPHOSPHATEMIA; KIDNEY METABOLISM; MALE; METABOLIC BONE DISEASE; MINERAL BONE DISORDER; OPEN STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROTONIN BLOOD LEVEL; URINARY EXCRETION; VITAMIN BLOOD LEVEL;

ADIPOKINES; CHRONIC KIDNEY DISEASE; FIBROBLAST GROWTH FACTOR-23; PHOSPHATE BINDERS.; WNT/Β-CATENIN SIGNALLING;

ACETATES; ADIPONECTIN; BETA CATENIN; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES; BONE MORPHOGENETIC PROTEINS; CALCIUM COMPOUNDS; CHELATING AGENTS; ENERGY METABOLISM; FEMALE; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; MALE; MIDDLE AGED; POLYAMINES; RENAL INSUFFICIENCY, CHRONIC; SEROTONIN; WNT PROTEINS;

EID: 84884948579     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft234     Document Type: Article

References (46)

1. Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990; 38: 193-211 (Pubitemid 20324978)
2. Moe S, Drueke T, Cunningham J et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953 (Pubitemid 43924257)
3. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38 (Pubitemid 44967731)
4. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 6: 2205-2215 (Pubitemid 41716454)
5. Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf- 1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-882
6. Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011; 26: 229-238
7. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378
8. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608
9. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
10. Isakova T, Xie H, Yang W et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
11. Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966
12. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
13. Shalhoub V, Shatzen EM, Ward SC et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012; 122: 2543-2553
14. Sabbagh Y, Graciolli FG, O'Brien S et al. Repression of osteocyte Wnt/â-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012; 27: 1757-1772
15. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?. Nephrol Dial Transplant 2004; 19(Suppl 1): i9-i13 (Pubitemid 38455637)
16. Hruska KA, Mathew S, Lund RJ et al. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol 2009; 29: 156-165
17. Fahrleitner-Pammer A, Herberth J, Browning SR et al. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 2008; 23: 1850-1858
18. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951 (Pubitemid 38822076)
19. Confavreux CB. Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int 2011; 121: S14-S19
20. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab 2006; 4: 341-348 (Pubitemid 44645074)
21. Parhami F, Tintut Y, Ballard A et al. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2011; 88: 954-960
22. Oda A, Taniguchi T, Yokoyama M. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 2001; 47: 141-150 (Pubitemid 33144840)
23. Singhal A, Farooqi IS, Cole TJ et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 2002; 106: 1919-1924. (Pubitemid 35176295)
24. Wallace AM, McMahon AD, Packard CJ et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-3056 (Pubitemid 34014056)
25. Reilly MP, Iqbal N, Schutta M et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 3872-3878 (Pubitemid 39071487)
26. Vanholder R, De Smet R, Glorieux G et al. European Uremic Toxin Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943 (Pubitemid 36513344)
27. Yadav VK, Balaji S, Suresh PS et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 2010; 16: 308-312
28. Rammohan M, Kalantar-Zadeh K, Liang A et al. Megestrol acetate in a moderate dose for the treatment of malnutritioninflammation complex in maintenance dialysis patients. J Ren Nutr 2005; 15: 345-355 (Pubitemid 40917294)
29. Shimizu H, Tsuchiya T, Sato N et al. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 1998; 21: 1470-1474 (Pubitemid 28405198)
30. Gammelmark A, Madsen T, Varming K et al. Low-dose fish oil supplementation increases serum adiponectin without affecting inflammatory markers in overweight subjects. Nutr Res 2012; 32: 15-23
31. Padhi D, Jang G, Stouch B et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011; 26: 19-26
32. Morvan F, Boulukos K, Clément-Lacroix P et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006; 21: 934-945 (Pubitemid 43788000)
33. Fulciniti M, Tassone P, Hideshima T et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114: 371-379
34. Isakova T, Gutiérrez OM, Smith K et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26: 584-591
35. Oliveira RB, Cancela ALE, Graciolli FG et al. Early Control of PTH and FGF23 in Normophosphatemic CKD Patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291.
36. Moester MJ, Papapoulos SE, Lowik CW et al. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010; 87: 99-107
37. Drueke TB, Lafage-Proust MH. Sclerostin: just one more player in renal bone disease? Clin J Am Soc Nephrol 2011; 6: 700-703.
38. Li X, Ominsky MS, Warmington KS et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24: 578-588
39. Thambiah S, Roplekar R, Manghat P et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012; 90: 473-480
40. Sato M, Takeda N, Sarui H et al. Association between serum leptin concentrations and mineral density and biochemical markers of bone turnover in adult men. J Clin Endocrinol Metab 2001; 86: 5273-5276 (Pubitemid 33070248)
41. Kokot F, Chudek J, Karkoszka H et al. Does PTH influence leptin concentration in haemodialysed uraemic patients? Nephron 1999; 82: 372-373. (Pubitemid 29385320)
42. Vlassara H, Uribarri J, Cai W et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 2012; 7: 934-942
43. Tsuji K, Maeda T, Kawane T et al. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha, 25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res 2010; 25: 1711-1723
44. Nikolov IG, Joki N, Nguyen-Khoa T et al. Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transplant 2012; 27: 505-513
45. Stinghen AE, Gonçalves SM, Bucharles S et al. Sevelamer decreases inflammation in parallel to a reduction in endotoxemia. Blood Purif 2010; 29: 352-356
46. Brandenburg VM, Schlieper G, Heussen N et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 2010; 25: 2672-2679